ជាមួយនឹងទិន្នន័យមហារីកអូវែដែលនឹងមកដល់ អ្នកវិភាគមើលឃើញថាមានការកើនឡើង 100% សម្រាប់ការព្យាបាល Mersana

• ធនាគារ Citi ផ្តួចផ្តើមការគ្របដណ្តប់លើ Mersana Therapeutics Inc (ផ្សារហ៊ុន NASDAQ: MRSN) ជាមួយនឹង Buy rating and a price target of $12. 

• The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

• Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

• If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

• The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

• On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

• In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

• The company announced a research collaboration and commercial license agreement with a subsidiary of ក្រុមហ៊ុន Merck KGaA (OTC៖ MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

• Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

• សកម្មភាពតម្លៃ: MRSN shares are up 10.48% at $6.43 on the last check Friday.

• រូបថតរបស់ Via Company

Latest Ratings for MRSN

កាលបរិច្ឆេទ	ក្រុមហ៊ុន	សកម្មភាព	ពី	ទៅ
ថ្ងៃទី2022 ខែកុម្ភៈ ឆ្នាំXNUMX	SVB Leerink	រក្សា		គំរូល្អជាង
ថ្ងៃទី2021 ខែសីហា ឆ្នាំXNUMX	HC Wainwright & Co.	ចាប់ផ្តើមគ្របដណ្តប់លើ		ចង់ទិញ
ថ្ងៃទី2021 ខែមិនា ឆ្នាំXNUMX​	ធនាគារ Credit Suisse	ចាប់ផ្តើមគ្របដណ្តប់លើ		អព្យាក្រឹត

View More Analyst Ratings for MRSN

មើលអត្រាអ្នកវិភាគចុងក្រោយ

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

អត្ថបទនេះបង្ហាញពីដំបូង benzinga.com

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។